Amgen Inc.

Amgen K-a, Inc.

Kirin-Amgen, Inc.

James F Smothers

Christopher Mehlin

Joel E Tocker

Jacques J Peschon

Douglas Pat Cerretti

Ai Ching Lim

Michael R Comeau

Kenneth Allan Brasel

David Fitzpatrick

Bo-Rin P Yoon

William C Fanslow, Iii

Jilin Sun

Stephen Foster

Revital Kariv

Ching Lim Ai

The present invention relates to IL-17 Receptor A (IL-17RA or IL-17R) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases mediated by IL-17 Receptor A activation by one or more IL-17 ligands. The present invention relates to the identification of neutralizing determinants on IL-17 Receptor A (IL-17RA or IL-17R) and antibodies that bind thereto. Aspects of the invention also include antibodies that compete for binding with the IL-17RA neutralizing antibodies described herein.

IL-17 receptor A antigen binding proteins

IL-17 Receptor A antigen binding proteins

The present disclosure provides compositions and methods relating to antigen binding proteins which bind to human thymic stromal lymphopoietin (TSLP), including antibodies. In particular embodiments, the disclosure provides fully human, humanized and chimeric anti-TSLP antibodies and derivatives of such antibodies. The disclosure further provides nucleic acids encoding such antibodies and antibody fragments and derivatives, and methods of making and using such antibodies including methods of treating and preventing TSLP-related inflammatory and fibrotic disorders.

Antigen binding proteins capable of binding thymic stromal lymphopoietin

Disclosed is an isolated human monoclonal antibody that specifically binds IL-17 Receptor A, or an IL-17 Receptor A binding fragment thereof, and inhibits IL-17A from binding and activating the receptor. The present disclosure also provides compositions and methods for treating diseases mediated by IL-17 Receptor A activation.

Antigen binding proteins that bind to human c-fms protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of c-fms to CSF-1, reduce monocyte migration into tumors, and reduce the accumulation of tumor-associated macrophages.

Human C-FMS antigen binding proteins

Human C-FMS antibodies

The present invention relates to IL-17 Receptor A antigen binding proteins, such as antibodies, and compositions and methods for diagnosing and treating diseases mediated by IL-17 Receptor A activation.

Methods of treating psoriasis using IL-17 receptor A antibodies

The present invention relates to IL-17 receptor A (IL-17RA or IL-17R) antigen binding proteins, such as antibodies, and the polynucleotide sequences encoding them, as well as host cells, expression vectors, and methods of making IL-17 receptor A antigen binding proteins.

Polynucleotides encoding IL-17 receptor A antigen binding proteins

Methods for treating conditions associated with c-fms

Methods of treating TSLP-related inflammatory disorders

Growing community of inventors

Quincy, MA, United States of America

James F Smothers